Insmed (INSM)
Health Care · Biotechnology · NASDAQ
Insmed is a biopharmaceutical company dedicated to transforming the lives of patients suffering from serious and rare respiratory and inflammatory diseases.
What Insmed does
Insmed Incorporated is a biopharmaceutical company focused on the development and commercialization of therapies for patients with serious and rare diseases. Its commercial portfolio includes treatments for chronic lung infections and other respiratory conditions, supported by a pipeline of clinical-stage product candidates.
Themes: rare disease therapies, respiratory medicine, inhaled drug delivery, orphan drugs
Fundamentals
- Price$123.98 as of 2026-08-24 close
- Market cap$27.1B as of 2026-08-24
- 1-year return-6.0% 2025-08-22 close $131.88 → 2026-08-24 close $123.98
- P/En/a negative earnings
- Net margin-76.9% as of 2026-08-24
- Gross margin+83.5% as of 2026-08-24
- ROE-111.3% as of 2026-08-24
- Debt / equity0.96 as of 2026-08-24
- Revenue growth (YoY)+66.7% FY2025 vs FY2024, SEC XBRL
- Revenue CAGR (3y)+35.2% SEC XBRL
- Beta0.72 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How INSM compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
INSM is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
51.8 #675 of 1,704 scored · #121 of 240 in Health Care
Momentum 64th: MACD momentum is positive; catalysts 58th: open-market insider buys in 90 days 20, the analyst consensus rating is unchanged since the prior reading; weakest is setup 31st: no Elliott-wave labelling currently fits its swings.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Insmed looks technically
Insmed (INSM) is trading 13.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 96 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 10 trading days ago. It is 40.9% below its highest point of the past year. Trading volume is unusually light — only about 40% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 13.6% below its 200-day average, the long-term trend line — a long-term downtrend | -13.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $110.73 | $110.73 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $145.59 | $145.59 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 122.21. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 96 trading days ago — a "death cross", a bearish long-term signal | 96 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control | 31.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 58.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($97.86 to $137.70) — its "stochastic" reading is 70 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 70.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $212.75 | $212.75 |
|---|---|---|
| From the 52-week high | it is 40.9% below its 52-week high (its highest price of the past year) | -40.9% |
| Above the 52-week low | it is 37.6% above its 52-week low (its lowest price of the past year) | +37.6% |
| Below the 52-week high | it is 40.9% below its highest point of the past year | 40.9% |
| Since a 20-day breakout | it made a new 20-day high about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day high about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $212.75 (set on 2025-12-02) | $212.75 |
| Given back of the 52-week move | over the past year its closes ranged ($94.17 to $211.41), and it has recovered roughly a quarter of its fall from last year’s high — 27% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $166.62 to $170.38. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 26.9% |
| From the all-time high | it is 40.9% below its all-time high | -40.9% |
| Nearest price level | it is trading 7.5% below a resistance level at $135.16 — a price it turned at three times since 2025-09-26, most recently on 2026-03-20. Since 2024-08-21 it has 10 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +7.5% |
| All-time low | its lowest closing price on record is $2.64 (set on 2011-11-25) | $2.64 |
| Above the all-time low | it is 4664.0% above its all-time low | +4,664% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 96% of the past ~6 months) | 96th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $5.36 between its high and its low — about 4.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $5.36 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $89.64 and $146.35 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $89.64 – $117.99 – $146.35 |
| Typical daily range (% of price) | its price moves about 4.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.3% |
| Stretch from the 200-day average | it is trading 3.7 daily ranges below its 200-day average price (13.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 40% of its 30-day average | 0.40× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a hammer | 2 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 29.5% above the previous close 11 sessions ago and has not traded back through the level it left behind at 99.02 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +29.5% |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 13.5 percentage points (the stock gained 15.8% while the market gained 2.3%) | +13.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 11.7 percentage points (the stock gained 14.8% while the market gained 3.1%) | +11.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 34.8 percentage points (the stock lost 23.7% while the market gained 11.1%) | -34.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 25.6 percentage points (the stock lost 5.2% while the market gained 20.5%) | -25.6% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.4% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.6% of the share price. | +7.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $126.89 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -0.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $130.68 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -3.8% |
Price levels it has turned at before
INSM last closed at $125.77 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $135.16 | Resistance | 7.5% above the last close | turned there three times · 2025-09-26 to 2026-03-20 |
| $138.22 | Resistance | 9.9% above the last close | turned there twice · 2025-09-15 to 2026-08-06 |
| $142.94 | Resistance | 13.7% above the last close | turned there twice · 2026-02-12 to 2026-05-05 |
| $105.21 | Support | 16.4% below the last close | turned there twice · 2025-07-17 to 2026-07-16 |
| $95.72 | Support | 23.9% below the last close | turned there twice · 2025-07-07 to 2026-08-03 |
| $81.77 | Support | 35.0% below the last close | turned there twice · 2025-02-06 to 2025-03-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $122.21.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $139.62 and $167.79 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · lagging the market · Trading at this year’s average price paid (anchored VWAP) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.22 mean, 1=Strong Buy…5=Strong Sell) — 22 analysts
- Mean price target$200.05 range $169.00 – $243.00; median $197.50
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for INSM
- Consensus EPS estimate-$0.3611 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Substantial historical losses and accumulated deficit with no assurance of achieving future profitability.","Significant reliance on the commercial success of its lead products, which face intense competition and regulatory/reimbursement challenges.","Material volatility in earnings due to the revaluation of contingent consideration liabilities related to prior acquisitions."]
What changed in the latest 10-Q
AI-assisted comparison of INSM's 10-Q filed 2026-05-07 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Added 'or European approval for BRINSUPRI' to first bullet point regarding BRINSUPRI approvals (2026-05-07 filing)
- Added 'or for BRINSUPRI outside of the US and Europe' to third bullet point regarding regulatory approvals (2026-05-07 filing)
- Removed:
- Removed 'including the risk that we will not successfully or in a timely manner complete the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE' from second bullet point (2025-10-30 filing)
- Removed 'or for brensocatib in Europe or Japan' from third bullet point (2025-10-30 filing)
- Removed 'or to permit the use of ARIKAYCE in the broader population of patients with MAC lung disease, among other things' from clinical trials bullet point (2025-10-30 filing)
- Removed 'risk that government healthcare reform materially increases our costs and damages our financial condition' as separate bullet point (2025-10-30 filing)
- Removed 'risk that our current and potential future use of artificial intelligence (AI) and machine learning may not be successful' as separate bullet point, replaced with different wording (2025-10-30 filing)
- Removed 'the risk that we could become involved in costly intellectual property disputes' and replaced with 'risk that we could become involved' (2025-10-30 filing)
- Removed 'the cost and potential reputational damage' and replaced with 'the cost and potential reputational damage' (wording change) (2025-10-30 filing)
- Removed 'our limited experience operating internationally' bullet point (2025-10-30 filing)
- Reworded:
- First bullet: Changed 'BRINSUPRI in the US' to 'BRINSUPRI in the US or Europe' and adjusted approval maintenance language (2026-05-07 filing)
- Second bullet: Removed specific language about confirmatory post-marketing clinical trial requirement for ARIKAYCE full approval (2026-05-07 filing)
- Third bullet: Changed 'for ARIKAYCE outside the US, Europe or Japan' to 'for ARIKAYCE outside of the US, Europe and Japan' and replaced 'or for brensocatib in Europe or Japan' with 'or for BRINSUPRI outside of the US and Europe' (2026-05-07 filing)
- Clinical trials bullet: Removed specific reference to 'to permit the use of ARIKAYCE in the broader population of patients with MAC lung disease, among other things' (2026-05-07 filing)
- Healthcare legislation bullet: Changed 'risk that government healthcare reform materially increases our costs and damages our financial condition' to 'risk that healthcare legislation or other government action materially adversely affects our business' (2026-05-07 filing)
- AI bullet: Changed 'risk that our current and potential future use of artificial intelligence (AI) and machine learning' to 'risk that our current and potential future use of AI and machine learning' (abbreviated 'AI and machine learning') (2026-05-07 filing)
- IP disputes bullet: Changed 'the risk that we could become' to 'risk that we could become' (removed 'the') (2026-05-07 filing)
- Pharmakon/OrbiMed bullet: Changed 'the risks and uncertainties associated with' to 'risks and uncertainties associated with' (removed 'the') (2026-05-07 filing)
- Notes:
- Text from newer filing appears truncated at 'goodwill impairment charges affecting our results of operations and financial condit', preventing full comparison of any items that may follow
- Text from older filing also appears truncated at 'laws that impact our ability to utilize c', preventing verification of complete final item
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 22 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 2 sells ($3M) — 1 selling insider
- Last 90 days0 buys · 22 sells ($12M) — 5 selling insiders
- Last 180 days0 buys · 45 sells ($26M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-06. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about INSM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 7 matched disclosures for INSM from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding INSM as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 38,318,962
- Reported value $6,265,916,596
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
INSM had 11,350,580 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
INSM had 5.20% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.14 days to cover at the same settlement.
- Reported short interest (shares) 11,350,580
- Short interest (% of shares outstanding) 5.20%
- Prior settlement (shares) 11,624,756
- Reported change -2.36%
- Days to cover (reported) 5.14
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- United Therapeutics (UTHR)
- Vertex Pharmaceuticals (VRTX)
- Gilead Sciences (GILD)
- Novartis (NVS)
- AstraZeneca (AZN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare INSM vs…
Insmed is found in…
Frequently asked questions
What does Insmed (INSM) do?
Insmed Incorporated is a biopharmaceutical company focused on the development and commercialization of therapies for patients with serious and rare diseases. Its commercial portfolio includes treatments for chronic lung infections and other respiratory conditions, supported by a pipeline of clinical-stage product candidates.
What sector is Insmed (INSM) in?
Insmed (INSM) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are Insmed's (INSM) competitors?
Notable peers of Insmed (INSM) include United Therapeutics, Vertex Pharmaceuticals, Gilead Sciences, Novartis and AstraZeneca. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in INSM?
Yes — we hold 7 matched STOCK Act disclosures for INSM from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Insmed (INSM) overbought or oversold right now?
Insmed (INSM) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on INSM come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.